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 Two of the most visible eff orts to address the “translational gaps” in moving biomedical research forward and the “lagging” effi  ciency of our clinical research infrastructure 
by the National Institutes of Health (NIH) was the creation of the 
network of 60 or so Clinical and Translational Science Awards 
(CTSAs) to establish “integrated homes” across academic medical 
centers, and establishing the National Center for Advancing 
Translational Sciences (NCATS). In July of this year, NIH 
also sponsored a report by the Institute of Medicine (IOM) 
of the National Academies of Sciences which outlined a series 
of recommendations to further refi ne the goals of the CTSA 
program to better realize its full potential. Each of these is an 
important and laudable step in an ever-increasing eff ort to build 
the right national infrastructure that can translate the impact of 
scientifi c advances into improved human health. 
 However, it is equally important that these “top-down” 
restructuring processes are also supplemented by appropriate 
“bottom-up” eff orts from investigators, grantees, and trainees at 
these academic medical centers. Th e Association for Clinical and 
Translational Sciences (ACTS), the professional organization that 
represents not only the CTSAs, but many non-CTSA academic 
medical centers, clinical and translational training programs, and 
patient-oriented researchers, provides just such a platform for the 
ground-level stakeholders to provide input into this process of 
national transformation through its policy statements, feedback 
from individual members, and public lobbying. In early Spring 
of this year, ACTS conducted a survey of the CTSA principal 
investigator (PI) group, responded to by 49 PIs, which asked for 
the most important short-term (i.e., which could be undertaken 
in a year) initiatives the CTSA consortium should be undertaking 
to impact clinical and translational research. Based on the results 
of this survey, ACTS then conducted a one-day facilitated retreat 
in Washington, DC, that was attended by 45 CTSA PIs or their 
representatives, translational researchers, as well as some of 
the ACTS Board members to further refi ne these thoughts. 
Described below are the recommendations from this meeting, 
which summarizes what the CTSA leadership group is thinking 
nationally. While this eff ort predated the IOM report, and was 
parallel to many NIH work groups, it is also remarkable how 
well these conclusions fi t with the NIH and IOM vision. Th e 
PI group was also convinced that not only all of the 61 CTSAs 
but most research-oriented academic centers should be asked to 
participate in the vision. 
 Focus on Future Translational Researchers 
 Four key interest areas are targeted under this mission by the PIs. 
First step is to create a community for the career development 
awardees (e.g., KL2, K23, K08 scholars) across institutions 
to network, share, and provide peer mentoring. Th e second 
recommendation is to build on the wealth of educational 
practices already in place by sharing established courses materials, 
curriculum, and virtual courses. It is estimated that hundreds of 
online courses exist already, but a number of roadblocks exist in 
permissions, fees, etc., which can be addressed by the consortium. 
Th ird, recognizing the need for fl exibility and alternative career 
paths, they recommend designing novel, modular career paths 
(such as moving from academics to industry) and training 
people for the emerging job markets. Finally, the PIs recommend 
starting a pipeline at the high school level to generate interest in 
biomedical careers and translational sciences early. 
 Facilitate Multisite Collaborations 
 Here, the priority recommendation is to focus on smaller sized 
collaborations (e.g., regional networks) that have a comprehensive 
platform for rapid study startups (e.g., shared clinical trials, 
Institutional Review Board). It is suggested that successful 
models and tools (e.g., contract forms, intellectual property 
sharing documents, etc.) be further promoted and shared. Th e 
number two priority is to develop a rare disease network for 
CTSAs that is based on existing resources within each centers’ 
electronic health records. Th is could involve developing a list 
of interested local champions and investigator pools for these 
projects, as well as having a fund of money available to the CTSAs 
for multicenter trials. Th e CTSA consortium members can create 
a rare disease repository/catalog through a central repository (e.g., 
the coordinating center) and make it available to the investigators 
across the country or the globe. 
 Expedite Preclinical Discoveries into Human Studies 
 Under this concept, the fi rst recommendation is to work with 
the preclinical divisions of NCATS and other NIH centers and 
institutes to develop an accessible library of drugs, compounds, 
high-throughput screens and model systems, and create 
tools to make such data available to investigators. Th e second 
recommendation was to establish a translational pipeline of 
resources that catalog both (1) the sequential drug discovery 
processes for unique targets that a clinical investigator may be 
looking for, and (2) a stepwise guidance required for human drug 
development for translational/basic science inventors. 
 Begin to Coordinate Informatics Infrastructure 
 Th e primary recommendation is to develop methods to access 
some aspects of the electronic health records (anonymized 
data sets; consented disease cohorts) for research purposes in 
small networks of fi ve to six CTSAs regionally. While regulatory 
challenges exist for large-scale sharing of data, tools and 
technologies can create specifi c registries and shared phenotypic 
data to enable researchers to collaborate within smaller regional 
networks. 
 Although all the CTSA PIs were highly enthusiastic about 
building a national infrastructure, they also recognize that an 
equally important responsibility for them is to transform their 
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local institutions and cultures for any of these ideas to fl ourish. 
They formulated the following statement expressing this 
sentiment: “All CTSAs should ideally have capacity across the 
entire T1–T4 spectrum with suffi  cient resources to make their 
core capacities signifi cant and meaningful. However, most CTSAs 
will not have suffi  cient strengths in all areas, and thus, each CTSA 
should select one or more areas of special strength for greater 
investment of their CTSA funds to yield larger benefi ts locally, 
and for the CTSA Consortium more broadly. Enhancing consortia 
activities is very important but this is only feasible if all CTSAs 
are strong at their own institution, and are able to contribute 
both by usual participation and by bringing special strengths to 
the Consortium.” As the president of ACTS, I fi nd this balance 
of local and national missions perfect. CTS
